Refine Search
(0)
(0)
(3)
(8)

Immunology

More than 65% of pipeline drugs are in early stages of development. Tumor necrosis factor, B lymphocyte antigen CD20 and nuclear receptor ROR gamma are some of the major targets under research for immunological diseases.

Heart Transplant Rejection - Pipeline Review, H1 2018

  • $2,000
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Heart Transplant Rejection - Pipeline Review, H1 2018’, provides an overview of the Heart Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Liver Transplant Rejection - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Liver Transplant Rejection - Pipeline Review, H2 2018’, provides an overview of the Liver Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under developm...

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018

  • $2,000
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2018’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics un...

Lung Transplant Rejection - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Lung Transplant Rejection - Pipeline Review, H2 2018’, provides an overview of the Lung Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under developmen...

Anaphylaxis - Pipeline Review, H2 2018

  • $2,000
  • November 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Anaphylaxis - Pipeline Review, H2 2018’, provides an overview of the Anaphylaxis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete ...

Myasthenia Gravis - Pipeline Review, H1 2019

  • $2,000
  • February 2019
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Myasthenia Gravis - Pipeline Review, H1 2019’, provides an overview of the Myasthenia Gravis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myasthenia...

Rheumatoid Arthritis - Pipeline Review, H1 2018

  • $2,500
  • June 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Rheumatoid Arthritis - Pipeline Review, H1 2018’, provides an overview of the Rheumatoid Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rheu...

Psoriasis - Pipeline Review, H2 2018

  • $2,500
  • September 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Psoriasis - Pipeline Review, H2 2018’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with a...